How Long Between Mounjaro and Wegovy: Timing Your Switch

The decision you are actually making when you consider switching

Switching from Mounjaro to Wegovy, or the other way, is not simply swapping one pen for another. You are moving between two distinct pharmacological mechanisms. Mounjaro activates both the GIP and GLP-1 receptors; Wegovy acts on GLP-1 alone. Both slow gastric emptying and reduce appetite, but the degree of effect differs, and your body will have adapted to whichever medicine you are currently on.

The decision involves three overlapping questions: how long the outgoing medicine is still pharmacologically active, what dose the incoming medicine should start at, and why you are switching in the first place. Someone switching because of side effects faces a different clinical picture from someone switching because supply of their current treatment has run out or because they have plateaued and want to try a different approach.

Our clinical team at nume fields this question regularly. The detail below sets out what is known, what remains uncertain, and why the timing has to be tailored rather than standardised. For a deeper look at how the two medicines compare on weight-loss outcomes, the Wegovy vs Mounjaro comparison sets those results alongside each other.

How long each medicine stays active — and why that governs the gap

Both tirzepatide and semaglutide have half-lives of approximately five days, meaning it takes around four to five weeks for plasma levels to fall to negligible concentrations after the last injection. Neither SmPC specifies a mandatory washout period for switching to the other, but that pharmacokinetic window is the starting reference point a prescriber uses.

Practically, most clinical conversations about how long to wait between Mounjaro and Wegovy land somewhere between two and four weeks after the last dose of the outgoing medicine, with the exact figure shaped by the dose you were on and how well you were tolerating it. A patient finishing a 15mg Mounjaro pen will carry more active drug for longer than someone who never titrated beyond 5mg.

Overlapping the two medicines is not appropriate. The additive GI load, and the overlapping effects on gastric motility, create a real risk of intensified nausea, vomiting and dehydration. This is not a theoretical concern: the detail on the gap after Mounjaro before starting Wegovy covers the pharmacokinetic reasoning in full.

There is also a starting-dose question on the incoming side. Even if you were on a high maintenance dose of Mounjaro, switching to Wegovy does not mean beginning at 2.4mg. A prescriber will typically re-titrate from a lower dose to manage tolerability, which is itself a reason the switch takes longer than patients expect.

Why results after switching can disappoint — and what the evidence says

Patients who switch from Mounjaro to Wegovy sometimes find the results less pronounced than they expected, and understanding why is part of making an informed decision. The comparison of weight-loss outcomes on Wegovy versus Mounjaro goes into the trial data in detail, but the short version is this: in the SURMOUNT-5 head-to-head trial, tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks. Moving from the more potent medicine to the less potent one mid-treatment is not always neutral.

That said, individual responses vary considerably. Some people do well on Wegovy after Mounjaro, particularly if they are switching because of GI intolerance rather than lack of efficacy. Others find that Wegovy feels less effective after Mounjaro, especially in the early weeks of re-titration when the dose is low. A prescriber familiar with your history is best placed to set realistic expectations before the switch happens.

It is also worth knowing that stopping either medicine without a clear plan tends to lead to weight returning. The evidence on what happens when treatment ends is discussed on the weight regain after stopping treatment page, relevant reading before any switch decision, because a poorly managed gap between medicines carries the same risk as stopping altogether.

The switching direction also matters, Wegovy to Mounjaro is a different conversation

Most of the questions our prescribers receive run Mounjaro to Wegovy, often because of supply, cost, or tolerability. But the reverse switch happens too, and the timing considerations differ slightly. Semaglutide has a marginally longer half-life than tirzepatide, so the washout on the Wegovy side may stretch a little further before a prescriber is comfortable initiating Mounjaro.

There is also a separate but related question about switching from Ozempic. Ozempic is the same active ingredient as Wegovy (semaglutide), but it is licensed for type 2 diabetes, not weight management. If that is the switch you are researching, the considerations around how long to wait when switching from Ozempic to Mounjaro differ by clinical context.

Cost is sometimes the driver behind a switch, and it is a legitimate one. The Mounjaro and Wegovy price comparison sets out what the two treatments currently cost through a private pharmacy. But cost alone is rarely the right basis for a switch. The prescriber weighs efficacy, tolerability, your current dose and your weight-management goals together. That is a richer conversation than a price list allows. To start it, begin your free consultation and a real clinician will review your answers the same day.